South Africa has one of the highest tuberculosis burdens in the world. In 2023, SA had an estimated TB incidence of approximately 500 per 100,000 people — among the highest globally. TB is not just a disease of poverty: it circulates in workplaces, taxis, homes, and healthcare settings. For medical aid members, TB is a Prescribed Minimum Benefit (PMB) condition — both acute treatment and continuation-phase medication are covered as a minimum benefit, regardless of plan tier. (TB is funded through its PMB status; it is not one of the Chronic Disease List (CDL) conditions.) Understanding the state/private divide, MDR-TB funding, and how the DOTS programme interacts with private scheme cover is essential.
What Is Tuberculosis?
TB is a bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs (pulmonary TB) but capable of infecting any organ (extrapulmonary TB — lymph nodes, spine, kidneys, brain, pericardium).
Transmission: Airborne — inhaled from respiratory droplets of an infectious person. TB is not easily transmitted by brief contact; prolonged close exposure (household contact, overcrowded spaces) carries the highest risk.
Latent vs active TB: - Latent TB infection (LTBI): The bacteria are present but dormant; the person is not infectious and has no symptoms. 5–10% of people with LTBI develop active TB over a lifetime (higher rate in immunocompromised individuals). - Active TB (pulmonary): Productive cough >2 weeks, fever, night sweats, weight loss, haemoptysis (blood in sputum). The person is infectious.
Drug resistance in SA: - MDR-TB (multidrug-resistant TB): Resistant to at least isoniazid and rifampicin — the two most important first-line drugs. SA has approximately 7,000–8,000 MDR-TB cases per year. - XDR-TB (extensively drug-resistant TB): Resistant to MDR-TB drugs + fluoroquinolones + injectable second-line drugs. Extremely difficult to treat; historically high mortality.
Is TB a PMB Condition?
Yes — TB is a PMB condition. It is not on the Chronic Disease List (CDL), but its PMB status carries the same "must fund regardless of plan" protection.
- PMB (Prescribed Minimum Benefits): Acute TB treatment (initial diagnosis, hospitalisation if required, intensive phase) is a PMB Diagnosis and Treatment Pair (code 937S). Your scheme must fund this.
- Continuation-phase medication: Ongoing TB medication (the continuation phase of treatment) must also be funded under the PMB at scheme DSP reference rate, regardless of plan tier. TB is not one of the CDL chronic conditions — but because it is a PMB Diagnosis and Treatment Pair, the funding protection is the same.
This means: From diagnosis through to treatment completion (6 months for drug-susceptible TB; longer for drug-resistant TB), your scheme must cover all medication and monitoring — irrespective of your plan's usual day-to-day limits.
Standard TB Treatment Regimen
Drug-susceptible TB (DS-TB) — standard regimen:
| Phase | Duration | Drugs | Abbreviation |
|---|---|---|---|
| Intensive phase | 2 months | Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | 2RHZE |
| Continuation phase | 4 months | Rifampicin + Isoniazid | 4RH |
Total duration: 6 months. These medications are funded under the PMB and must be covered by your scheme regardless of plan tier.
MDR-TB: Treatment regimen has evolved significantly. The WHO-endorsed BPaL (Bedaquiline + Pretomanid + Linezolid) regimen and the BPaLM regimen are now preferred over older injectable-based protocols. Treatment duration: 6–9 months (new regimens) vs the older 18–24 months. These are expensive medications — Bedaquiline alone costs substantially more than first-line TB drugs. MDR-TB treatment is PMB-covered in the private sector.
XDR-TB: Treated at specialist centres; usually in the public sector at designated MDR/XDR units.
How Does Medical Aid Cover TB?
| Service | PMB? | Typical cover | Notes |
|---|---|---|---|
| Sputum culture and sensitivity (diagnosis) | Yes — PMB | Pathology benefit (PMB) | Critical for drug-resistance detection |
| Chest X-ray | Yes — PMB | Radiology benefit | Baseline + monitoring |
| GeneXpert MTB/RIF (molecular rapid test) | Yes — PMB | Pathology benefit | Rapid MDR detection; standard of care in SA |
| HIV test at TB diagnosis | Yes — PMB | Pathology benefit | All TB patients should be tested for HIV |
| First-line TB drugs (RHZE/RH) | Yes — PMB | Chronic medication benefit | Full 6-month course |
| MDR-TB drugs (Bedaquiline, Pretomanid, Linezolid) | Yes — PMB | Hospital/specialised benefit | Expensive; pre-auth may be required |
| Hospitalisation (severe TB, MDR-TB, complications) | Yes — PMB | Hospital benefit | |
| Monthly monitoring bloods (LFTs, creatinine) | Yes — PMB | Pathology benefit | Liver function monitoring during RHZE phase |
| TB specialist consultation | Yes — PMB (initial) | Day-to-day (ongoing) | |
| DOT (directly observed therapy) support | State programme | Via NDoH/state | Available free at clinics; private schemes do not fund DOT per se |
| Nutritional support | No | Day-to-day (limited) | TB causes weight loss; nutritional recovery is important |
| TB contact tracing | State function | Via NDoH |
State vs Private: The Practical Reality
Most TB treatment in SA occurs in the public sector. The NDoH DOTS programme provides: - Free diagnosis - Free first-line TB medication - DOT (directly observed therapy) support at local clinics - Free sputum follow-up
Private medical aid members can choose: To be treated in the private sector (scheme-funded PMB) or to access the state TB programme free of charge. Many medical aid members with TB choose state clinics precisely because the treatment is the same, free, and DOT-supported.
When the private route makes sense: - You need to work during treatment and require flexible appointment times - You have HIV and complex co-management requiring private physician coordination - You have suspected or confirmed drug-resistant TB requiring rapid access to molecular testing and MDR specialists - You have extrapulmonary TB (spinal TB, TB meningitis, pericardial TB) requiring hospital-level management
HIV-TB Co-infection — Critical SA Context
TB is the leading cause of death in HIV-positive people globally. In SA, ~60% of TB patients are HIV co-infected.
For HIV-positive medical aid members with TB: - HIV is a CDL condition; TB is a PMB condition — both must be managed simultaneously - Antiretroviral therapy timing during TB treatment is critical (usually started within 2–8 weeks after TB treatment initiation) - Drug-drug interactions between rifampicin and some ARVs require ARV regimen adjustment (rifampicin induces CYP450, reducing levels of some ARVs) - All of this is PMB-covered in the private sector
Biologic Therapy and TB Risk
Patients on TNF inhibitors (adalimumab, etanercept, infliximab) for RA, AS, psoriasis, or IBD are at significantly increased risk of TB reactivation (latent TB becomes active).
Before starting a TNF inhibitor: All patients must be screened for latent TB infection — TST (tuberculin skin test) and/or IGRA (interferon-gamma release assay). Positive result = preventive TB treatment before starting biologic.
If active TB develops on a TNF inhibitor: The biologic must be suspended; TB treatment initiated. The biologic can be restarted after 2+ months of TB treatment with specialist guidance.
Key Questions to Ask Your Scheme
- Please confirm my TB is registered as a PMB condition — what documentation is required? (Usually a diagnosis letter from your doctor with ICD-10 A15-A19 codes.)
- Are all my TB medications funded under the PMB? First-line drugs should be; confirm MDR-TB drugs separately.
- Is a TB specialist or pulmonologist referral covered under PMB? Initial diagnosis workup and specialist initiation of treatment should be PMB.
- If I have MDR-TB, are Bedaquiline and Pretomanid covered? Request written confirmation.
Talk to Eldon
TB has PMB protection — your scheme must fund the full 6-month treatment course regardless of plan tier. AURA ensures PMB registration is activated from diagnosis so treatment is covered as a minimum benefit throughout.
See which plans pay for infectious disease coverage →